Evaluation of new antimicrobials for the hospital formulary. Policies restricting antibiotic use in hospitals

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 31, Issue SUPPL. 4, 2013, Pages 45-50

  Pujol, Miquel ^a   Delgado, Olga ^b   Puigventós, Francesc ^b   Corzo, Juan E ^c   Cercenado, Emilia ^d   Antonio Martínez, José ^e  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b HOSPITAL UNIVERSITARIO SON ESPASES   (Spain)

^c HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^d HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^e UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Antibiotic resistance; Antimicrobial stewardship programs (ASP); Antimicrobial use; Restrictive antimicrobial policies

Indexed keywords

AMIKACIN; ANTIBIOTIC AGENT; AZTREONAM; CARBAPENEM DERIVATIVE; CEFAZOLIN; CEFTAROLINE; CEPHALOSPORIN DERIVATIVE; CIPROFLOXACIN; DAPTOMYCIN; FIDAXOMICIN; GENTAMICIN; GREPAFLOXACIN; METRONIDAZOLE; PIPERACILLIN PLUS TAZOBACTAM; TEMAFLOXACIN; VANCOMYCIN;

ALTERNATIVE MEDICINE; ANTIBIOTIC RESISTANCE; ARTICLE; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG SAFETY; DRUG SCREENING; DRUG USE; ECONOMIC EVALUATION; EVIDENCE BASED MEDICINE; HEALTH CARE POLICY; HOSPITAL; HOSPITAL PHARMACY; HUMAN; PRACTICE GUIDELINE; PRESCRIPTION; PUBLIC HEALTH; RISK ASSESSMENT; SPAIN;

ANTIBIOTIC RESISTANCE; ANTIMICROBIAL STEWARDSHIP PROGRAMS (ASP); ANTIMICROBIAL USE; POLÍTICAS RESTRICTIVAS DE USO DE ANTIBIÓTICOS; PROGRAMAS DE OPTIMIZACIÓN DEL USO DE ANTIBIÓTICOS; RESISTENCIA ANTIBIÓTICA; RESTRICTIVE ANTIMICROBIAL POLICIES; USO DE ANTIBIÓTICOS;

ANTI-BACTERIAL AGENTS; DRUG UTILIZATION; FORMULARIES, HOSPITAL; HOSPITALS; HUMANS;

EID: 84886894185     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/S0213-005X(13)70132-0     Document Type: Article

References (48)

1. F. Puigventós, B. Santos-Ramos, A. Ortega, and E. Durán-García Structure and procedures of the pharmacy and therapeutic committees in Spanish hospitals Pharm World Sci 32 2010 767 775
2. Ministry of Health, Social Services and Equality. Criteria and recommendations for treatment with Boceprevir and Telaprevir for Chronic Hepatitis C (HCV) monoinfected patients. Directorate General of Basic Services National Health System and Pharmacy [accessed 2013-Feb-2]. Available at: http://www.msc.es/profesionales/farmacia.
3. R. Gil Marín, B. Santos-Ramos, S. Flores-Moreno, E. Briones-Pérez, and J. Bautista-Dove Consensus method to update the model GINF application Farm Hosp 35 2011 121 127
4. F. Puigventós, P. Ventayol, I. Martínez-López, and T. Requena Project Genesis: approach to a uniform methodology for evaluating drugs E. López-Briz, J.L. Poveda, Evaluation and selection of drugs based on evidence-based medicine 2009 Published by the association for research, development and innovation in hospital pharmacy 149 194
5. Group of Innovation, Assesment, Standarisation and Research in the Selection of Drugs. MADRE Program. Procedures Manual. GENESIS-SEFH. Version 4.0 2012 [accessed 2013-Feb-2]. Available at: http://gruposdetrabajo.sefh.es/ genesis/genesis/basesmetodologicas/programamadre/index.html.
6. Servicio Andaluz de Salud: Proceso de actualización de la Guía Farmacoterapéutica de Hospitales de Andalucía [accessed 2013-Oct-3]. Available at: http://www.juntadeandalucia.es/ servicioandaluzdesalud/library/plantillas/externa.asp?pag=././publicaciones/ datos/321/html/Home.htm.
7. Committee for Medicine Products for Human Use (CHMP). European Public Assessment Report (EPAR) Zinforo. Fosamil Ceftaroline DCI. EMA/472628/2012 [accessed 2013-Feb-2]. Available at: http://www.ema.europa.eu/docs/en-GB/ document-library/EPAR-Public-assessment-report/human/002252/WC500132587.pdf.
8. Committee for Medicine Products for Human Use (CHMP). European Public Assessment Report (EPAR) Dificlir fidaxomicin EMA/857570/2011 [accessed 2013-Feb-2]. Available at: http://www.ema.europa.eu/docs/en-GB/document-library/ EPAR-Public-assessment-report/human/002087/WC500119707.pdf
9. D.S. Budnitz, D.A. Pollock, K.N. Weidenbach, A.B. Mendelsohn, T.J. Schroeder, and J.L. Annest National surveillance of emergency department visits for outpatient adverse drug events JAMA 296 2006 1858 1866
10. K.A. Sprandel, and K.A. Rodvold Safety and tolerability of fluoroquinolones Clin Cornerstone Suppl 3 2003 S29 S36
11. D.L. Paterson Collateral damage from cephalosporin or quinolone antibiotic therapy Clin Inf Dis 38 Suppl 4 2004 S341 S345
12. L.R. Peterson Squeezing the antibiotic balloon: the impact of antimicrobial classes on emerging resistance Clin Microbiol Infect 11 Suppl 5 2005 4 16
13. J. Rodríguez-Baño, J.R. Paño-Pardo, L. Álvarez-Rocha, A. Asensio, E. Calbo, and E. Cercenado Programs for optimizing the use of antibiotics (PROA) in Spanish hospitals: GEIH-SEIMC SEFH and SEMPSPH consensus document. Enferm Infecc Microbiol Clin 30 2012 22 e1-23
14. T.H. Dellit, R.C. Owens, J.E. McGowan Jr., D.N. Gerding, R.A. Weinstein, and J.P. Burke Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America guidelines for developing an institutional program to enhance antimicrobial stewardship Clin Infect Dis 44 2007 159 177
15. M. Griffith, M. Postelnick, and M. Scheetz Antimicrobial stewardship programs: methods of operation and suggested outcomes Expert Rev Anti Infect Ther 10 2012 63 73
16. R.H. Drew, R. White, C. MacDougall, E.D. Hermsen, and R.C. Owens Jr. Society of Infectious Diseases Pharmacists. Insights from the Society of Infectious Diseases Pharmacists on antimicrobial stewardship guidelines from the Infectious Diseases Society of America and the Society for Healthcare Epidemiology of America Pharmacotherapy 29 2009 593 607
17. E.E. Reed, K.B. Stevenson, J.E. West, K.A. Bauer, and D.A. Goff Impact of formulary restriction with prior authorization by an antimicrobial stewardship program Virulence 4 2013 158 162
18. R.W. Coleman, L.C. Rodondi, S. Kaubisch, N.B. Granzella, and P.D. O'Hanley Cost-effectiveness of prospective and continuous parenteral antibiotic control: experience at the Palo Alto Veterans Affairs Medical Center from 1987 to 1989 Am J Med 90 1991 439 444
19. J.J. Rahal, C. Urban, D. Horn, K. Freeman, S. Segal-Maurer, and J. Maurer Class restriction of cephalosporin use to control total cephalosporin resistance in nosocomial Klebsiella JAMA 280 1998 1233 1237
20. J.P. Burke Antibiotic resistance-squeezing the balloon? JAMA 280 1998 1270 1271
21. P. Toltzis, T. Yamashita, L. Vilt, M. Green, A. Morrissey, and S. Spinner-Block Antibiotic restriction does not alter endemic colonization with resistant gram-negative rods in a pediatric intensive care unit Crit Care Med 26 1998 1893 1899
22. A.C. White Jr., R.L. Atmar, J. Wilson, T.R. Cate, C.E. Stager, and S.B. Greenberg Effects of requiring prior authorization for selected antimicrobials: expenditures, susceptibilities, and clinical outcomes Clin Infect Dis 25 1997 230 239
23. S.L. Pestotnik Expert clinical decision support systems to enhance antimicrobial stewardship programs: insights from the society of infectious diseases pharmacists Pharmacotherapy 25 2005 1116 1125
24. D.M. Connor, S. Binkley, N.O. Fishman, L.B. Gasink, D. Linkin, and E. Lautenbach Impact of automatic orders to discontinue vancomycin therapy on vancomycin use in an antimicrobial stewardship program Infect Control Hosp Epidemiol 28 2007 1408 1410
25. R. Agarwal, and D.N. Schwartz Procalcitonin to guide duration of antimicrobial therapy in intensive care units: a systematic review Clin Infect Dis 53 2011 379 387
26. N. Singh, P. Rogers, C.W. Atwood, M.M. Wagener, and V.L. Yu Short-course empiric antibiotic therapy for patients with pulmonary infiltrates in the intensive care unit. A proposed solution for indiscriminate antibiotic prescription Am J Respir Crit Care Med 162 2000 505 511
27. D.L. Paterson The role of antimicrobial management programs in optimizing antibiotic prescribing within hospitals Clin Infect Dis 42 Suppl 2 2006 S90 S95
28. S.K. Fridkin Routine cycling of antimicrobial agents as an infection-control measure Clin Infect Dis 36 2003 1438 1444
29. M.H. Kollef Is there a role for antibiotic cycling in the intensive care unit? Crit Care Med 29 Suppl 2001 N135 N142
30. D.N. Gerding, T.A. Larson, R.A. Hughes, M. Weller, C. Shanholtzer, and L. Peterson Aminoglycoside resistance and aminoglycoside usage: ten years of experience in one hospital Antimicrob Agents Chemother 35 1991 1284 1290
31. D. Gruson, G. Hilbert, F. Vargas, R. Valentino, C. Bebear, and A. Allery Rotation and restricted use of antibiotics in a medical intensive care unit: impact on the incidence of ventilator-associated pneumonia caused by antibiotic-resistant gram-negative bacteria Am J Respir Crit Care Med 162 2000 837 843
32. D.P. Raymond, S.J. Pelletier, T.D. Crabtree, T.G. Gleason, L.L. Hamm, and M.D. Pruett Impact of a rotating empiric antibiotic schedule on infectious mortality in an intensive care unit Crit Care Med 29 2001 1101 1108
33. J.A. Martínez, J.M. Nicolás, F. Marco, J.P. Horcajada, G. García-Segarra, and A. Trilla Comparison of antimicrobial cycling and mixing strategies in two medical intensive care units Crit Care Med 34 2006 329 336
34. A.N. Ginn, A.M. Wiklendt, H.F. Gidding, N. George, J.S. O'Driscoll, and S.R. Partridge The ecology of antibiotic use in the ICU: homogeneous prescribing of cefepime but not tazocin selects for antibiotic resistant infection PLoS One 2012 e38719
35. E.A. Domínguez, T.L. Smith, E. Reed, C.C. Sanders, and W.E. Sanders Jr. A pilot study of antibiotic cycling in a hematology-oncology unit Infect Control Hosp Epidemiol 21 Suppl 1 2000 S4 S8
36. A. Cumpston, M. Craig, M. Hamadani, J. Abraham, G.R. Hobbs, and A.R. Sarwari Extended follow-up of an antibiotic cycling program for the management of febrile neutropenia in a hematologic malignancy and hematopoietic cell transplantation unit Transpl Infect Dis 15 2012 142 149
37. B.R. Levin, and M.J.M. Bonten Cycling antibiotics may not be good for your health Proc Natl Acad Sci USA 101 2004 13101 13102
38. M.J. Bonten, D.J. Austin, and M. Lipsitch Understanding the spread of antibiotic resistant pathogens in hospitals: mathematical models as tools for control Clin Infect Dis 33 2001 1739 1746
39. C.T. Bergstrom, M. Lo, and M. Lipsitch Ecological theory suggests that antimicrobial cycling will not reduce antimicrobial resistance in hospitals Proc Natl Acad Sci USA 101 2004 13285 13290
40. S. Bonhoeffer, M. Lipsitch, and B.R. Levin Evaluating treatment protocols to prevent antibiotic resistance Proc Natl Acad Sci USA 94 1997 12106 12111
41. Y. Takesue, K. Nakajima, K. Ichiki, M. Ishihara, Y. Wada, and Y. Takahashi Impact of a hospital-wide programme of heterogeneous antibiotic use on the development of antibiotic-resistant gram-negative bacteria J Hosp Infect 75 2010 28 32
42. A. Sandiumenge, E. Díaz, A. Rodríguez, L. Vidaur, L. Canadell, and M. Olona Impact of diversity of antibiotic use on the development of antimicrobial resistance J Antimicrob Chemother 57 2006 1197 1204
43. H.J. Van Loon, M.R. Vriens, A.C. Fluit, A. Troelstra, C. Van der Werken, and J. Verhoef Antibiotic rotation and development of gram-negative antibiotic resistance Am J Respir Crit Care Med 171 2005 480 487
44. H.L. Evans, M.L. Milburn, G. Hughes, R.L. Smith, T.W. Chong, and D.P. Raymond Nature of gram-negative rod antibiotic resistance during antibiotic rotation Surg Infect 6 2005 223 231
45. P. Damas, J.L. Canivet, D. Ledoux, M. Monchi, P. Melin, and M. Nys Selection of resistance during sequential use of preferential antibiotic classes Intensive Care Med 32 2006 67 74
46. I. Ziha-Zarifi, C. Llanes, T. Kohler, J.C. Pechere, and P. Plesiat In vivo emergence of multidrug-resistant mutants of Pseudomonas aeruginosa overexpressing the active efflux system MexA-MexB-OprM Antimicrob Agents Chemother 43 1999 287 291
47. C. Plüss-Suard, A. Pannatier, A. Kronenberg, K. Mühlemann, and G. Zanetti impact of antibiotic use on carbapenem resistance in Pseudomonas aeruginosa: Is there a role for antibiotic diversity? Antimicrob Agents Chemother 57 2013 1709 1713
48. A.M. Bal, A. Kumar, and I.M. Gould Antibiotic heterogeneity: from concept to practice Ann N Y Acad Sci 1213 2010 81 91